CAS: 6236-05-1; Cis-5-Nitrofuran-2-Aldoxime

上下游产品

5-Nitro-Furfural-(E)-Oxime 7197-93-5
5-硝基糠醛 5-Nitrofurane-2-Carboxaldehyde 698-63-5

📜糠醛置于钠羟基氨基磺酸盐,硫酸,硝酸体系中,化学反应生成 硝呋醛肟标准品
参考文献:Nenitzescu; Bucur,Revue De Chimie,Academie De La Republique Populaire Roumaine,1956,Vol. 1,# 1,P. 155,163
标题:Nenitzescu; Bucur,Revue De Chimie,Academie De La Republique Populaire Roumaine,1956,Vol. 1,# 1,P. 155,163

专利信息

专利号:US-2003180254-A1
优先权日:1995-05-26
标题:Immunologic enhancement with intermittent interleukin-2 therapy
发明人：LANE H CLIFFORD; KOVACS JOSEPH A; FAUCI ANTHONY S
权利人:GOVT OF THE USA AS REPRESENTED
摘要:A method for activating a mammalian immune system entails a series of IL-2 administrations that are effected intermittently over an extended period. Each administration of IL-2 is sufficient to allow spontaneous DNA synthesis in peripheral blood or lymph node cells of the patient to increase and peak, and each subsequent administration follows the preceding administration in the series by a period of time that is sufficient to allow IL-2 receptor expression in peripheral or lymph node blood of the patient to increase, peak and then decrease to 50% of peak value. This intermittent IL-2 therapy can be combined with another therapy which targets a specific disease state, such as an anti-retroviral therapy comprising, for example, the administration of AZT, ddI or interferon alpha. In addition, IL-2 administration can be employed to facilitate in situ transduction of T cells in the context of gene therapy. By this approach the cells are first activated in vivo via the aforementioned IL-2 therapy, and transduction then is effected by delivering a genetically engineered retroviral vector directly to the patient.

专利号:US-5696079-A
优先权日:1993-05-19
标 题:Immunologic enhancement with intermittent interleukin-2 therapy
发明人：LANE H CLIFFORD; KOVACS JOSEPH A; FAUCI ANTHONY S
权利人:US HEALTH
摘要:A method for activating a mammalian immune system entails a series of IL-2 administrations that are effected intermittently over an extended period. Each administration of IL-2 is sufficient to allow spontaneous DNA synthesis in peripheral blood or lymph node cells of the patient to increase and peak, and each subsequent administration follows the preceding administration in the series by a period of time that is sufficient to allow IL-2 receptor expression in peripheral or lymph node blood of the patient to increase, peak and then decrease to 50% of peak value. This intermittent IL-2 therapy can be combined with another therapy which targets a specific disease state, such as an anti-retroviral therapy comprising, for example, the administration of AZT, ddI or interferon alpha. In addition, IL-2 administration can be employed to facilitate in situ transduction of T cells in the context of gene therapy. By this approach the cells are first activated in vivo via the aforementioned IL-2 therapy, and transduction then is effected by delivering a genetically engineered retrovital vector directly to the patient.

专利号:US-6548055-B1
优先权日:1993-05-19
标题:Immunologic enhancement with intermittent interleukin-2 therapy
发明人：LANE H CLIFFORD; KOVACS JOSEPH A; FAUCI ANTHONY S
权利人:US HEALTH
摘要:A method for activating a mammalian immune system entails a series of IL-2 administrations that are effected intermittently over an extended period. Each administration of IL-2 is sufficient to allow spontaneous DNA synthesis in peripheral blood or lymph node cells of the patient to increase and peak, and each subsequent administration follows the preceding administration in the series by a period of time that is sufficient to allow IL-2 receptor expression in peripheral or lymph node blood of the patient to increase, peak and then decrease to 50% of peak value. This intermittent IL-2 therapy can be combined with another therapy which targets a specific disease state, such as an anti-retroviral therapy comprising, for example, the administration of AZT, ddI or interferon alpha. In addition, IL-2 administration can be employed to facilitate in situ transduction of T cells in the context of gene therapy. By this approach the cells are first activated in vivo via the aforementioned IL-2 therapy, and transduction then is effected by delivering a genetically engineered retroviral vector directly to the patient.